Truist Financial Reaffirms Buy Rating for Lantheus (NASDAQ:LNTH)

Lantheus (NASDAQ:LNTH)‘s stock had its “buy” rating restated by equities researchers at Truist Financial in a research note issued to investors on Monday,Benzinga reports. They currently have a $115.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $98.00. Truist Financial’s price target indicates a potential upside of 22.12% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. Mizuho boosted their price objective on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a report on Tuesday, March 17th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.71.

Lantheus Stock Performance

Shares of LNTH stock traded up $1.11 during midday trading on Monday, hitting $94.17. 292,431 shares of the company were exchanged, compared to its average volume of 919,166. The firm has a market capitalization of $6.13 billion, a P/E ratio of 22.70 and a beta of -0.08. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The firm’s 50 day moving average price is $79.69 and its two-hundred day moving average price is $68.87. Lantheus has a 52 week low of $47.25 and a 52 week high of $95.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts anticipate that Lantheus will post 4.26 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Hantz Financial Services Inc. increased its position in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. First Horizon Corp acquired a new position in Lantheus during the 3rd quarter worth approximately $26,000. Smartleaf Asset Management LLC increased its position in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Parallel Advisors LLC increased its position in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in Lantheus during the 2nd quarter worth approximately $36,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.